TargetAMD – 1st Project Period

The first project period of 18 months has been conducted successfully. In vitro experiments evaluated the final plasmid construct and the transfer to in vivo experiments had already started. In a pre-clinical setting, using pre-clinical grade plasmids the transfection procedure was validated and optimised. The in vivo approach will be tested in animal models to establish the procedure with regard to pharmacokinetcs, efficacy and safety aspects.

1. May 2014
Categories: Target AMD